Real-world outcomes from the UK IBD Registry on second-line biologic therapy following anti-TNF exposure in Crohn's disease: results from the BISCUITS study.

ABSTRACT:

Background

Selection of second-line therapy in Crohn's disease (CD) patients after failure of first-line TNFα-inhibitor (TNFi) therapy to optimise outcomes remains challenging in real-world clinical practice.

Objectives

This study aimed to provide real-world outcomes of CD patients who failed first-line TNFi therapy and switched to either another TNFi or to a biologic with a different mechanism of action. Patients were stratified as to whether they switched because of primary non-response or secondary loss of response to initial TNFi.

Design

Retrospective cohort study.

Methods

CD patients whose first biologic therapy was a TNFi and switched to another biologic therapy between 26 August 2015 and 31 March 2021 were identified in records held by the UK IBD Registr

SUBMITTER: Taylor F 

PROVIDER: S-EPMC12304648 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature